Cooperman Barnabas Medical Center Places Final Steel Beam for New Cancer Center Building

2023-09-26T12:01:00

(BPT) – Cooperman Barnabas Medical Center (CBMC) — part of RWJBarnabas Health, the largest and most comprehensive academic healthcare system in New Jersey — recently raised the final steel beam on its $225 million, freestanding Cancer Center, scheduled for 2025 completion.

Cancer survivors, oncology department staff, board members, and donors added their signatures to the steel beam of the five-story, 137,000-square-foot facility located in Livingston, New Jersey.

The outpatient facility will serve as the northern hub for the integrated oncology services offered by RWJBarnabas Health and Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center.

“Cooperman Barnabas Medical Center is a regional leader in cancer care, and with the construction of this state-of-the-art facility, we are setting a new standard for top-quality care,” said Richard L. Davis, the hospital’s President and CEO. “With world-class amenities and a team that includes some of the top cancer specialists in the nation, the new Cancer Center will be a premier destination for patient-centered and research-driven cancer care in this region and beyond.”

“There is absolutely nothing more important to our community than having best-in-class health care. The creation of a state-of-the-art cancer center here at CBMC represents one of the most significant events in this community and continues the ongoing growth and transformation of the Medical Center,” said Bruce Schonbraun, Chair of the Board of Trustees at CBMC.

“Our vision of reimagining cancer care could not have occurred without the generosity and support of our many donors. We are grateful for their support and to everyone who has played a role in bringing this project to life,” Schonbraun added.

Patients will have access to medical, surgical, and radiation oncology services at the new Cancer Center, with amenities that include a wig and prosthetic studio, yoga classes, music therapy, and psychosocial support services. Private infusion rooms and short-term and extended-stay facilities will also be available.

“The Cancer Center at Cooperman Barnabas Medical Center is part of an overall major investment by RWJBarnabas Health and Rutgers Cancer Institute to transform oncology services across the state including the construction of the Jack and Sheryl Morris Cancer Center, the state’s first freestanding cancer hospital,” said Steven K. Libutti, M.D., Director of Rutgers Cancer Institute of New Jersey and Senior Vice President, Oncology Services at RWJBarnabas Health.

The medical center’s partnership with Rutgers Cancer Institute of New Jersey provides patients access to the most advanced treatment options, including clinical trials, CAR T-cell therapy, immunotherapy, and precision medicine.

“This new Cancer Center will be synonymous with clinical excellence, collaboration, and a commitment to integrated care, delivered by world-class physicians and specialists,” said Michael Scoppetuolo, M.D., Medical Director of the Cancer Center at CBMC. “This is what the future of cancer care looks like in the Garden State and beyond. I’m honored to be a part of it.”

“Cancer treatment is getting more targeted and precise every year,” added Alison Grann, M.D., Chair of the hospital’s Department of Radiation Oncology and the Northern Region Director of Radiation Oncology, RWJBarnabas Health. “The Cancer Center will provide patients with the most advanced multidisciplinary, patient-centric cancer care available in one central location.”

More information about the new center is available online, at rwjbh.org/cbmccancercenter.

How new legislation can help address the health care workforce shortage

2023-09-22T05:01:00

(BPT) – If you’ve recently scheduled medical appointments or procedures, you may have noticed longer wait times than you expected. There’s a reason for that: The U.S. currently needs more than 17,000 additional healthcare practitioners to keep up with demand, according to the Health Resources and Services Administration. Although healthcare provider shortages are occurring across the country, the problem is particularly acute in underserved rural and urban areas.

One specific area of need is anesthesia care. Certified Registered Nurse Anesthetists (CRNAs) are often the only anesthesiology providers in rural hospitals and are the predominant providers in underserved communities, yet current regulations regarding how these highly qualified healthcare professionals can practice limit the ability of CRNAs to care for patients to the full extent of their training and experience.

To address this issue, the Improving Care and Access to Nurses (ICAN) Act introduced in Congress with bipartisan support will help eliminate unnecessary barriers to practice, so patients and healthcare facilities can fully benefit from the expertise of CRNAs for anesthesia care.

Senators Jeff Merkley (D-OR) and Cynthia Lummis (R-WY) introduced the ICAN Act (Senate Bill 2418) in the Senate, joining more than a dozen representatives from both parties sponsoring the House version of the bill. The ICAN Act would remove barriers for advanced practice registered nurses (APRNs) such as CRNAs, allowing them to provide more comprehensive healthcare services to patients nationwide. The American Association of Nurse Anesthesiology (AANA), plus over 200 other nursing and healthcare organizations, support the legislation, which will remove unnecessary supervision of CRNAs and provide access to CRNA services in Medicaid.

“CRNAs play a vital role in maintaining critical access in communities across the country,” said AANA President Dru Riddle, PhD, DNP, CRNA, FAAN. “However, superfluous regulations serve as barriers to expanding care, especially when those same communities face a shortage of providers. This critical legislation helps ensure everyone who needs access to high-quality care provided by advanced practice registered nurses such as CRNAs can have it.”

CRNA training and experience

CRNAs and other APRNs are trained at the master’s or doctoral level to provide anesthesia and pain management services, treat and diagnose illnesses, advise the public on health issues, manage chronic disease, provide care during pregnancy, childbirth and the postpartum period, order and interpret diagnostic tests and prescribe medication and non-pharmacologic treatments.

Despite the critical role APRNs such as CRNAs serve in the U.S. healthcare system, some federal statutes and regulations as well as institutional rules currently limit their practice, preventing them from practicing to the full extent of their education and clinical training.

CRNAs currently represent over 80% of anesthesia providers in rural counties. Rural hospitals and critical access hospitals often rely on independently practicing CRNAs for anesthesia care so the facilities can provide a wide range of surgical care, including obstetrics and pain management, close to home, when and where patients need it most. Even with CRNAs’ vital role in maintaining critical access in communities nationwide, current Medicare restrictions require physician supervision of CRNAs. However, in many cases, there are no physician anesthesia providers available in a rural hospital to offer this unnecessary supervision, so the federal requirement creates a barrier to expanding care and worsens the current provider shortage, especially in underserved communities — without improving patient outcomes.

Additional support for the ICAN Act

Removing barriers to practice for CRNAs and other APRNs has widespread support. The National Academies of Science, Engineering and Medicine recommended in “The Future of Nursing 2020-2030: Charting a Path to Achieve Health Equity” that “all relevant state, federal and private organizations enable nurses to practice to the full extent of their education and training by removing practice barriers that prevent them from more fully addressing social needs and social determinants of health and improve health care access, quality and value.”

These recommendations are echoed by multiple bipartisan stakeholders including the American Enterprise Institute, Brookings Institution, the Bipartisan Policy Center and AARP.

Improving access to care

Passing the ICAN Act will mean removing many barriers between patients and nurses in Medicare and increasing access to care for all Americans. Removing redundant supervision requirements for CRNAs will help lower costs in Medicare and Medicaid programs — and ensure proper reimbursement for services to maintain the highest standard and quality of care.

“We’ve seen how much nurses can do when they’re allowed to reach the full potential of their education and scope of practice,” added Riddle. “Removing barriers between nurses and patients is critical for achieving a more compassionate, efficient, affordable and equitable healthcare system for all Americans.”

Learn more about the ICAN Act and how you can support this life-saving legislation at AnesthesiaFacts.com.

Reach Out and Play: Fueling multigenerational connection through game nights

2023-09-20T15:59:00

(BPT) – When you were younger, you might have had “family game night,” huddled around the kitchen table with dice and tokens. Besides the happy memories this brings, those game nights may actually help boost one’s health. Social connections, sense of purpose and an active mind can be key parts of healthier aging. Coming together to play games can be one way to encompass all three — while helping to reduce isolation.

In light of this, Ageless Innovation’s Reach Out and Play campaign, sponsored by AARP, will host board game events across the country through the end of the year.

Various organizations will host board game events across the country, and people are also encouraged to host their own with family and friends. These activities will bring people of all ages together through the power of play, and create meaningful connections for older adults.

Social isolation and loneliness for older adults can have a massive effect on their health. Loneliness has been found to lead to health risks, such as depression, cognitive decline, hypertension and more. Social isolation may lead to cardiovascular disease, a reduced quality of life and other health issues. Personal connections, no matter what the activities, can help foster better health.

“Social connection, camaraderie, and even some problem-solving — all of these things can be important contributors to the health of older adults,” said Dr. Philip Painter, chief medical officer at UnitedHealthcare Medicare & Retirement. “Events like this can bring people of all ages together for fun, but also drive a sense of wellness, which is so vital as we age.”

For information on Reach Out and Play, including how to find and register for an event in your area, visit aarp.org/agelessplay. And, check out reimagined versions of Scrabble, The Game of Life, and Trivial Pursuit — interpretations that encourage intergenerational play.

If you’re 65, there is one piece of mail you shouldn’t ignore this month

2023-09-20T13:31:00

(BPT) – Are you or someone you love on Medicare? As the annual Medicare Annual Enrollment Period approaches (it starts on October 15 and runs through December 7), no doubt your mailbox will be flooded with letters, flyers and postcards from insurance companies and brokers pushing many Medicare options. But the one piece of mail you need to pay attention to is your current Medicare plan’s Annual Notice of Change, commonly referred to as ANOC.

All Medicare Advantage Plans and Part D Prescription plans are required to send out this important letter before the end of September. They must tell you if your current plan is changing in any way, because if there are changes that you don’t like, you have the right to change your plan during the Annual Enrollment Period. And yes, Medicare plans can change from year to year — and sometimes not for the better. What if your prescription drugs are no longer covered? Your doctor leaves the network? Your premium suddenly increases? Your co-payments jump? Protect your health and your wallet … read that ANOC letter!

Each insurance company has their own version of the ANOC letter, which may be up to 20 pages long, so grab a cup of coffee and get comfortable! Here are 6 things to look out for when reviewing your ANOC.

  1. Change in plan premium. It’s likely that a plan’s premium may change from year to year. How much is dependent on what the individual carrier changes, but you could even see a plan with a $0 monthly premium change to having an actual dollar amount for you to pay.
  2. Changes in co-pays. Check to make sure your doctor co-pays, including primary and specialists in and out of network, have not changed.
  3. Network changes. This will show you if your doctors and pharmacies are no longer in your plan’s network or are no longer a preferred provider.
  4. Drug list changes. It’s so important that you look at this list, also called the drug formulary. Prescriptions fall in and out of coverage or change price levels, so please review to see if your drugs are still covered and if there are any new restrictions.
  5. Out-of-pocket maximum. This is the amount of money you will pay out-of-pocket for all Medicare-covered expenses. Make sure to review this section to see if your out-of-pocket limit has changed.
  6. Additional benefits in Medicare Advantage plans. For those with a Medicare Advantage plan, you may have coverage for additional benefits like dental, vision, hearing, telehealth and more.

Caution! If you ignore the ANOC letter and you do nothing during the Annual Enrollment Period, your current plan will renew for 2024 — and you won’t be able to make any changes until October 2024.

But if you review your plan’s annual notice and decide that your current plan may not be right for you in the coming year, it’s time to consider changing your plan for 2024. According to the Kaiser Family Foundation, “The average Medicare beneficiary in 2023 has access to 43 Medicare Advantage plans, the largest number of options ever.” That means there are more plans for you to choose from this year (great news!).

Confused? Overwhelmed? Free help is just a phone call away. ClearMatch™ Medicare is dedicated to making Medicare easier to understand so you can choose the plan that’s right for you. Their highly trained licensed agents are patient and helpful, and if they find you are already in a great plan, they’ll tell you so. If you’d like help, call 1-888-441-7030 (TTY:711) for a free, no-obligation Medicare review, Monday-Friday, 9 a.m.-9 p.m., Saturday, 9 a.m.-6 p.m. (ET) or visit ClearMatchMedicare.com, open 24-7.

The Power of Self-Advocacy in Pompe Disease

2023-09-14T23:01:00

(BPT) – When Amy was trying to get back in shape after giving birth to her second child, she noticed lower back pain and core weakness she was struggling to re-strengthen. After numerous attempts at physical therapy and consulting with numerous doctors, she finally met with a neurologist and received a diagnosis of Late-Onset Pompe Disease (LOPD), a rare, genetic disorder which causes progressive weakness and can affect the major muscle groups used for breathing and mobility.

Amy’s self-advocacy and motivation to understand what was happening to her body has helped her to keep moving forward day by day, while living with a rare disease, with the help and support of her family, friends and care team. In fact, living with a rare disease may not be as rare as you would think – affecting one in 10 Americans, there are more than 7,000 known rare diseases in the U.S.

Here are some tips to ensure you too are proactively prioritizing your health, listening to your body and getting checked out by a doctor if you are experiencing symptoms such as shortness of breath, trouble eating or chewing or difficultly walking.

  • Listen to Your Body: As someone who exercised regularly, Amy immediately took notice of her fatigue and difficulties when exercising. Speaking with physicians from multiple disciplines, eventually including a neurologist, helped lead her toward a Pompe diagnosis.
  • Communicate Your Needs: While at work as a physician’s assistant, a job that often requires being on your feet for many hours, Amy takes breaks when needed, and remains mindful of how she is feeling throughout the day. These adjustments in her schedule have helped Amy to continue working and be there for her own patients. Similar to Amy, it is important to let others know when you need help and support if you are experiencing a challenging moment.
  • Work With Your Doctor to Monitor Your Progress: Two months after her Pompe diagnosis, Amy began an enzyme replacement therapy (ERT) regimen every two weeks and visited her doctor every six months to monitor progress. In between those appointments, Amy paid close attention to her body to inform her doctor on any changes, helping ensure she maintained the muscle function she had for as long as possible. Taking note of any new symptoms also helped her make the most of her conversations with her doctor, and as a result, better-informed care decisions.
  • Understand Your Options: When diagnosed with a rare disease, knowledge is power. Making the effort to familiarize oneself with rare diseases, symptoms and resources could be key to a diagnosis and proper treatment. Even though Amy was stable on the treatment she was using, she stayed up-to-date on scientific innovations. A year after beginning her initial ERT, Amy learned about NEXVIAZYME (avalglucosidase alfa-ngpt), a monotherapy for LOPD given every two weeks. After talking it through with her doctor, she decided to change her treatment. By keeping an open dialogue with her physician and advocating for herself, Amy was able to take the best next step for her to manage her LOPD.

Like Amy and her journey, remaining persistent and curious is a critical part of one’s journey. “I hope my story helps other people. At the end of the day, everybody has something they’re dealing with. But we will get through it, if we use each other for support,” said Amy, who is being treated with NEXVIAZYME for her LOPD.

For those living with Pompe disease, it is essential to continuously speak to your healthcare provider about ways to support the management of the disease. Being informed of Pompe disease, its signs and symptoms and potential treatment options are all key to helping advocate for yourself or a loved one. If you are currently living with LOPD and on an enzyme replacement therapy, but your symptoms are worsening or you are unable to do the things you want to do, talk to your doctor to see if NEXVIAZYME could be a treatment option for your late-onset Pompe disease management.

Patient stories reflect the real-life experiences of persons diagnosed with LOPD who have been prescribed NEXVIAZYME. However, individual experiences may vary. Patient stories are not necessarily representative of what another person using NEXVIAZYME may experience.

This patient was compensated for their time in creating this content.

INDICATION

NEXVIAZYME (avalglucosidase alfa-ngpt) is used for the treatment of patients 1 year of age and older with late-onset Pompe disease [lysosomal acid alpha-glucosidase (GAA) deficiency].

IMPORTANT SAFETY INFORMATION

WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS

Hypersensitivity Reactions Including Anaphylaxis

If you are taking NEXVIAZYME, you should know that severe and potentially life threatening allergic-type reactions known as anaphylaxis and severe hypersensitivity reactions have occurred during and after NEXVIAZYME treatment. You should seek immediate medical care if signs and symptoms of anaphylaxis or hypersensitivity reactions occur. If such a reaction is severe enough, your doctor may decide to immediately discontinue the infusion and provide immediate medical care. Appropriate medical support measures may be administered during your infusion, and you may require close observation during and after NEXVIAZYME administration.

Infusion-Associated Reactions (IARs)

If you are taking NEXVIAZYME, you should know that severe IARs have occurred during and after NEXVIAZYME treatment. If severe IARs occur during your NEXVIAZYME infusion, your doctor may decide to immediately discontinue the infusion and provide appropriate medical care. If you have an acute underlying illness at the time of NEXVIAZYME infusion you may be at greater risk for IARs. If you have advanced Pompe disease you may have compromised heart and breathing function, which may put you at a higher risk of severe complications from IARs.

Risk of Acute Cardiorespiratory Failure in Susceptible Patients

If you are likely to develop fluid volume overload, or have acute underlying breathing problems or compromised heart or breathing function that may require fluid restriction, there may be a risk of worsening of your heart or breathing status during NEXVIAZYME infusion. Your doctor may decide that close observation during NEXVIAZYME administration may be necessary.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions Including Anaphylaxis: See Boxed WARNING. Your doctor may decide to give you antihistamine, anti-fever and/or steroid medications before your infusions. Your doctor should consider the risks and benefits of restarting the infusion if you have a severe hypersensitivity reaction (including anaphylaxis) to NEXVIAZYME. If a mild or moderate hypersensitivity reaction occurs, your healthcare provider may slow the infusion rate or temporarily stop the infusion.

Infusion-Associated Reactions (IARs): See Boxed WARNING. Your doctor may decide to give you medications before your infusions to decrease the risk of IARs; however, IARs may still occur after receiving these medications. If mild or moderate IARs occur, your healthcare provider should consider decreasing the infusion rate or temporarily stopping the infusion which may help improve the symptoms.

Risk of Acute Cardiorespiratory Failure in Susceptible Patients: See Boxed WARNING.

ADVERSE REACTIONS

The most common adverse reactions (>5%) were headache, fatigue, diarrhea, nausea, joint pain, dizziness, muscle pain, itching, vomiting, shortness of breath, rash, “pins-and-needles” sensation, and hives.

Please see full Prescribing Information for complete details, including Boxed WARNING.

Sanofi does not provide medical advice, diagnosis, or treatment. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

A simple guide to living a more plant-based lifestyle

2023-09-14T10:27:00

(BPT) – Whether you’re seeking a better approach to your diet, a more environmentally conscious lifestyle or both, you’re in good company. Last year’s plant-based food market in the U.S. totaled $8 billion, up 7% from 2021 — and interest in plant-forward eating is not slowing down. Whatever your reasons for wanting to make this change, you probably have questions. Do you want to go vegan, or just vegetarian? Can you add a few more plant-based foods to your day and reap the benefits?

“A diet centered around fruits, vegetables and other plant-based foods can deliver nutrients your body uses for energy while avoiding many of the drawbacks associated with eating meat,” said Dr. Luigi Gratton, M.D., M.P.H. and vice president of Training for Herbalife. “Eating whole fruits, vegetables, nuts, seeds and grains is beneficial because they contain a plethora of nutrients that support healthy function across all bodily systems.”

Although any effort to incorporate more plant-based foods into your routine offers benefits, it may be difficult to do all at once. To make lasting change, experts recommend taking one step at a time. New ways of shopping, cooking and eating take getting used to — as does adjusting to new flavors and textures.

What is a plant-based lifestyle?

“Plant-based” means you primarily eat food derived from plants. This is similar to the term “plant-forward,” emphasizing whole grains, fruits, vegetables, legumes, seeds and nuts — but not limiting you to those foods. Versions of plant-based diets include:

Vegetarian: You abstain from eating animal products including meat, poultry or fish. Vegetarians consider it acceptable to eat animal by-products, such as milk and eggs, if the animals are kept in adequate conditions.

Vegan: In the strictest version of the plant-based approach, you eliminate any food of animal origin. In addition to avoiding meat and seafood, vegans also avoid dairy products, eggs and honey. Vegan foods never contain byproducts of animal agriculture like lard, whey or gelatin.

Flexitarian: An alternative to vegetarian, flexitarians focus on fruits, veggies, whole grains, legumes and nuts, but occasionally include meat, poultry, fish or eggs. When incorporating meat, flexitarians choose organic, free-range, pasture-raised or grass-fed beef, chicken or turkey. This is a great option if you’re just starting to experiment with a plant-based lifestyle.

How do you know you’re getting enough nutrients?

One question for anyone considering going vegetarian or vegan is whether they’ll get enough protein and other nutrients for optimal health. Beyond seeking plant-based forms of protein like beans and legumes, nuts and seeds, iron-rich tofu and spinach, and whole grains like quinoa, you can add supplements to support your well-being with plant-based certified products like those from the Herbalife V Line.

“While following a plant-based lifestyle can be a very healthy way of eating, it may be tough to meet all your goals. For example, vegans seek good options to increase or meet their protein goals, including supplementation,” said Gratton. “Plant-based certified products like the shakes in the Herbalife V line can help you hit your macro target while taking out the guesswork of plant-based living.”

The product line offers four plant-based certified products to help simplify plant-based nutrition:

Plant-based Protein Shakes: Available in classic and chocolate flavors, their 20 grams of protein (pea, pumpkin seeds and chia) satisfies hunger, reduces food cravings, maintains lean muscle tone, sustains energy and promotes healthy skin. The shakes are also a source of non-heme iron.
Greens Booster: Formulated with special blends derived from organic fruits, vegetables, superfood powders and green tea, this is an easy way to add more fruit and vegetable ingredients to your daily routine.
Immune Support: Contains vitamins C, D and zinc to help balance and support daily immune health.*
Digestive Support: Oat and guar fibers support a healthy gut, digestion and regularity.*

Herbalife V products are backed by science and rigorously tested for quality. All products are certified USDA Organic, non-GMO-verified, Kosher, as well as Plant-based and Vegan by FoodChain ID. They’re formulated with no soy or dairy, with no artificial sweeteners or flavors. Herbalife V is available in the U.S. and Puerto Rico exclusively through Herbalife independent distributors. Learn more at Herbalife.com/herbalifev.

Ready to get started? Begin adding one plant-based meal per day, then slowly increase to three a day over the course of a month or two. Before you know it, you’ll be following a plant-forward lifestyle. Making one small change at a time can help improve your daily diet and overall wellness.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Five Misconceptions About Enlarged Prostate

2023-09-12T08:01:00

(BPT) – Enlarged prostate, also known as benign prostatic hyperplasia (BPH), is a condition in which the prostate grows and presses on the urethra. This can obstruct the flow of urine and can disrupt a man’s life by causing uncomfortable symptoms, like having a weak stream or difficulty starting or stopping urination.[1] BPH is a common condition in older men, yet there are many misconceptions about treatment options, their side effects and what it means to live with BPH.[2]

Here are five common myths about BPH.

1. Only older men get BPH

While it’s true that up to 90% of men develop BPH by age 85, younger men can develop the condition too. Did you know 50% of men by age 60 will develop BPH?2 Some data suggest that approximately 1 in 12 men between the ages of 41 and 50 can also suffer from BPH. Men with BPH may experience waking up throughout the night to urinate or the feeling that the bladder is not empty, even after relieving themselves.[3]

2. BPH is connected to prostate cancer

BPH and prostate cancer may present similar symptoms, but having BPH does not increase the risk of developing prostate cancer.[4] However, since they do have similar symptoms, such as a frequent urge to urinate or a weak urinary stream, it is important to talk to a doctor for an accurate diagnosis.4

3. If BPH symptoms aren’t severe, treatment isn’t needed

When BPH symptoms aren’t severe, health care providers may recommend a “watch and wait” approach, which may include behavior modifications and therapies.[5] Examples include:

  • Avoiding fluids prior to bedtime or before going out
  • Reducing consumption of diuretics such as caffeine or alcohol
  • Pelvic floor muscle training

If the “watch and wait” approach isn’t effective, minimally invasive treatment options may provide relief. It is important to speak with a healthcare provider to determine the best course of action to help maintain quality of life. By delaying treatment, men, particularly those who are older, may experience worsening BPH symptoms.[6]

4. Most treatment options for moderate or severe BPH require significant recovery time

For moderate or severe forms of BPH, treatment options beyond lifestyle adjustments may be recommended. For patients who want to avoid the potential side effects that come with some surgical procedures, minimally invasive procedures, such as Rezūm™ Water Vapor Therapy, may be an option. Rezūm Therapy uses the energy stored in water vapor to reduce the size of the prostate and provide lasting relief. It works by releasing water vapor into the excess prostate tissue that’s causing bothersome urinary symptoms.[7] Over time, the body’s natural healing response absorbs the treated tissue, shrinking the prostate.[8] Most patients who receive Rezūm Therapy return to regular activities within a few days after treatment and see symptom improvement within two weeks.[9]

5. Multiple treatments are required to treat BPH

Treatment options for BPH can include medication to manage symptoms, minimally invasive procedures and surgery.[10] While some patients require multiple treatments, others may not. A clinical study found that patients treated with Rezūm Therapy had sustained symptom relief and preserved their sexual function out to five years — with only 4.4% of study participants requiring another surgical treatment for BPH symptoms.7

For more information about BPH and treatment options, including Rezūm Water Vapor Therapy, visit Rezum.com.

References


[1] Mayo Clinic. Benign prostatic hyperplasia. Available at: https://www.mayoclinic.org/diseases-conditions/benign-prostatic-hyperplasia/ symptoms-causes/syc-20370087. Accessed May 2023.

[2] Harvard Health. The growing problem of an enlarged prostate gland. Available at: https://www.health.harvard.edu/mens-health/the-growing-problem-of-an-enlarged-prostate-gland. Accessed May 2023.

[3] Nimeh, Tony, et. al. Benign Prostatic Hyperplasia: Review of Modern Minimally Invasive Surgical Treatments. Seminars in Interventional Radiology. 2016 Sep; 33(3): 244–250.

[4] National Cancer Institute. Understanding Prostate Changes: A Health Guide for Men. Available at: https://www.cancer.gov/types/prostate/understanding-prostate-changes. Accessed May 2023.

[5] UpToDate. Patient education: Benign prostatic hyperplasia (BPH) (Beyond the Basics). Available at: https://www.uptodate.com/contents/benign-prostatic-hyperplasia-bph-beyond-the-basics. Accessed May 2023.

[6] Elkoushy MA, Elshal AM, Elhilali MM. Changing patients’ profile presenting for surgical management of benign prostatic hyperplasia over the past 16 years: A single-centre perspective. Can Urol Assoc J. 2015 Nov-Dec;9(11-12):372-8.

[7] McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of Rezūm water vapor thermal therapy for treatment of moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021 Sep;206(3):715-24

[8] Data on file with Boston Scientific.

[9] McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy ablation: A multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016 May;195(5):1529-38.

[10] Cleveland Clinic. Benign Prostatic Enlargement/Hyperplasia (BPE/BPH). Available at: https://my.clevelandclinic.org/health/diseases/9100- benign-prostatic-enlargement-bph. Accessed May 2023.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

All treatments have inherent and associated risks. The Rezūm System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH. It is indicated for men ≥ 50 years of age with a prostate volume 30cm3 ≤ 80cm3. The Rezūm System is also indicated for treatment of prostate with hyperplasia of the central zone and/or a median lobe. Potential risks include but are not limited to painful urination (dysuria), blood in the urine (hematuria), blood in the semen (hematospermia), decrease in ejaculatory volume, suspected urinary tract infection (UTI), and urinary frequency, retention or urgency. You should talk with your doctor about benefits and risks before moving forward with any treatment option.

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.

Rezum.com is a website owned by Boston Scientific.

©2023 Boston Scientific Corporation or its affiliates. All rights reserved. URO-1669006-AA SEPT 2023

Ready to Take Charge of Your High Cholesterol? Here’s What You Can Do

2023-09-11T08:01:00

(BPT) – “I have a plan.” When Linda walked into her cardiologist’s office in 2022, she felt confident. This visit felt different—empowering, even. The retired nurse had been battling high levels of what’s known as “bad” cholesterol (aka low-density lipoprotein cholesterol or LDL-C) for more than 30 years—a struggle that millions of Americans know all too well. But this time around, she came prepared with a different game plan.

When lifestyle changes and statins (the most prescribed drugs used to lower cholesterol levels) aren’t enough, giving up on lowering your bad cholesterol isn’t an option. In honor of National Cholesterol Education Month this September, Linda is sharing her inspirational health journey to help other people struggling with high levels of bad cholesterol reach their personal LDL-C goals.

Who knows more about you than…you? While doctors are there to offer support and help every step of the way, it’s important to always advocate for yourself. And what is the very first step to opening a productive, two-way conversation? Honesty. If you’ve been doing everything as recommended by your doctor—such as replacing french fries with fruits, skipping that glass of wine each night, going for a walk around the block five times a week—and aren’t seeing results, say something.

Linda knows firsthand there’s nothing to be ashamed of. “The usual diet and exercise routine and my statin regimen that my doctor recommended was no longer getting me to my goal,” she shares. Over time, it became more of a priority to manage her overall health. Due to her family’s history with heart disease, Linda took her regular chest pains seriously as soon as they first began in the early 2000s. After a 20-minute episode resulted in an emergency cardiogram, her doctor informed her of plaque buildup and she had a stent put in. Despite her many attempts to get the situation under control, there always seemed to be more left to do to help get her bad cholesterol under control. This episode was the wake-up call she needed to make a change. “It felt like I was stuck in a cycle of putting in the effort and ending up disappointed, and the only way out was to try something new.”

That’s exactly why preparation is essential when it comes to doctor’s visits. It doesn’t hurt to familiarize yourself with how high levels of bad cholesterol affects the body and the steps you can take to moderate it. It could simply mean spending an hour or two reading through materials online, or asking family and friends about their experiences: which treatment did they decide on? How did it make them feel? How easy was it to stick to the prescription schedule? Educating yourself allows you to arrive with specific questions for your doctor, and in certain cases, even have a potential add-on treatment already in mind.

BE YOUR OWN ADVOCATE: 5 QUESTIONS TO ASK YOUR DOCTOR

  1. How effective is this medication for lowering my bad cholesterol?
  2. How can I find a medication that works for my lifestyle?
  3. How does this medication work?
  4. What side effects does the medication have and can it be taken with other medications?
  5. How much will the medication cost?

When Linda first heard of a new medication, called Leqvio® (inclisiran), that could help lower her bad cholesterol, it was as if a lightbulb went off in her mind. And after researching more about the twice-yearly injection (after two initial injections), she took the idea straight to her cardiologist and nurse practitioner.1

Leqvio is meant for patients with heart disease and those with an increased risk of developing heart disease, whose bad cholesterol levels still aren’t where they need after taking statins and making positive lifestyle choices.1 Leqvio works by stopping certain proteins in the liver from being made, thereby allowing your liver to remove more bad cholesterol from the bloodstream for six months with one dose.1

“Leqvio is the first and only treatment proven to lower bad cholesterol by 50% and keep it low with two doses a year,” explains Dr. Stephanie Saucier, MD and Director of the Women’s Heart Wellness Program at Hartford Hospital.1 “What I especially like is that it works with the body’s natural processes and can fit into your lifestyle. Having an effective bi-annual treatment can allow people to live their lives and not have to consistently plan around treatment.”

The journey to lowering bad cholesterol isn’t always simple. Finding a care team that empathizes with your experiences and tailors treatment to your needs can make life so much easier. In Linda’s case, for example, twice-yearly Leqvio made sense for her lifestyle. “I’ve always loved to travel. The fact that my husband and I can freely book a trip to Italy, instead of worrying about staying local for my frequent appointments or injections, is life-changing,” she shared. Working with your doctor to find the right routine and medication can help you feel confident in managing your bad cholesterol and allow you to focus on the things you love most.

High levels of bad cholesterol is a bad problem. But making the choice to improve it is a brave step towards a healthier future. The good news? It’s treatable. The better news? There are tools to help you reach your cholesterol goals, such as Leqvio, which along with a statin was shown to lower bad cholesterol levels by 50% in patients during each six-month dosing interval.1 It’s all about knowing your body and teaming up with your health care provider to find what works. Take it from Linda: “It all starts with one conversation. I can’t say it enough: talk to your doctor. You can be one conversation away from reaching your cholesterol goals.”

To learn more about Leqvio, visit Leqvio.com.

Sponsored by Novartis Pharmaceuticals Corporation

What is Leqvio?

LEQVIO (inclisiran) is an injectable prescription medicine used along with diet and other cholesterol-lowering medicines in adults with high blood cholesterol levels called primary hyperlipidemia (including a type of high cholesterol called heterozygous familial hypercholesterolemia [HeFH]) to reduce low-density lipoprotein (LDL-C) or “bad” cholesterol.

IMPORTANT SAFETY INFORMATION

The most common side effects of LEQVIO were: injection site reaction (including pain, redness, and rash), joint pain, and chest cold.

These are not all the possible side effects of LEQVIO. Ask your health care provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please click here for Leqvio full Prescribing Information.

Reference
1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp.

Licensed from Alnylam Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

East Hanover, New Jersey 07936-1080 © 2023 Novartis 8/23 298504

Moving to a new beat: How one dancer found hope after a rare disease diagnosis

2023-09-08T14:01:02

(BPT) – For dancers, their body is their instrument. This is certainly true for Hannah, a young dancer who has always loved the performing arts and expressing herself through movement and music.

“My story will always start and end with my body as art,” Hannah said. “Growing up, I learned I could create something beautiful with different parts of my body, from the sound of my voice to the way I move my muscles through dance.”

While studying to become a theater artist in college, Hannah started encountering symptoms she couldn’t explain, including severe abdominal pain and nausea. At first, she assumed it was related to her menstrual cycle. But when the symptoms became worse and persisted while interfering with her daily life, she went to the emergency room to try and find answers.

This was the start of Hannah’s journey to figure out what was happening to her body. Doctors tried to treat her for gastrointestinal disorders, but her symptoms kept recurring. The pain in her abdomen, low energy, severe nausea and dizziness made it impossible for her to do what she loved — and finally landed her in the hospital’s ICU.

“I was under constant medical supervision, and I was terrified,” Hannah explained. “This was a body that I trusted and thought I knew well, but suddenly I felt betrayed and confused. The doctors still weren’t sure what was happening to me.”

Eventually, Hannah was discharged from the hospital with no answers. Hannah stated, “I tried to return to my ballet class, but I had lost 15 pounds in the course of a week, and I couldn’t even stand in first position without feeling dizzy. I was like a musician who had lost their instrument.”

While Hannah was resting and recovering, her doctors worked to determine the correct diagnosis — though they did have suspicions of what could be causing her issues.

It wasn’t until a class trip to London that she finally received answers. While visiting the home of William Shakespeare, abdominal pain sent her to the emergency room again. After numerous tests, the British doctor came in and diagnosed her with acute hepatic porphyria (AHP).

What is AHP?

Acute hepatic porphyria (AHP) is a family of rare genetic diseases characterized by potentially life-threatening attacks and, for some people, chronic debilitating symptoms that negatively impact daily functioning and quality of life. There are 4 types of AHP: acute intermittent porphyria (AIP), hereditary coproporphyria, (HCP), variegate porphyria (VP) and ALAD-deficiency porphyria (ADP); with AIP being the most common type of AHP. AHP can affect people of any race, ethnicity, age or gender; however, approximately 80% of people diagnosed with AHP are women. Because AHP can have a wide range of symptoms that may resemble other diseases, it can be difficult to diagnose.

“I learned that AHP is a genetic disease that causes symptoms when toxins build up in the liver and then are released throughout the body,” said Hannah. “My symptoms are usually triggered by my period. I worked with my doctor to develop a management plan and learned to live a new normal as I integrated this into my life.” In people with AHP, there are certain triggers that can cause symptoms of the disease. Some known triggers include hormonal fluctuations, infection, stress, use of certain medications, alcohol consumption and fasting/low-carbohydrate diets.

Back on her feet

Eventually, Hannah’s doctor recommended that she try GIVLAARI® (givosiran), explaining that it was an injection administered once a month by a healthcare professional. Her doctor informed her of the possible risks and side effects, including the possibility of severe allergic reactions, liver problems, kidney problems and injection site reactions. GIVLAARI can also cause increased levels of blood homocysteine (a type of amino acid).

Hannah has experienced side effects when receiving her injections. “When I receive my injections, I sometimes experience a little bit of a stinging sensation at the injection site, as well as fatigue.”

Since starting treatment with GIVLAARI, Hannah has experienced fewer AHP attacks. “It almost feels like the spotlight of my life is back on me. Of course, this is just my experience, and everyone’s will be different.”

Currently, Hannah teaches numerous styles of dance, choreographs regionally and weaves yoga and dance into her preschool students’ daily routines. “When I teach, it’s from the heart. That’s where my strength comes from now,” she says.

As Hannah reflects on her AHP journey, she explains, “Having AHP has taught me that although the show goes on, part of being resilient is knowing when to rest and take time for yourself, and when to ask for help. After everything I’ve been through, I’ve realized my body is a work of art now more than ever. I want patients and doctors who encounter this condition to know that while the pain is real, so is the strength to overcome the pain.”

Please see Important Safety Information for GIVLAARI below.

To learn more about GIVLAARI, visit GIVLAARI.com.

Hannah is an Alnylam patient ambassador and was paid to share her story.

IMPORTANT SAFETY INFORMATION

Do not use GIVLAARI if you have ever had a severe allergic reaction to GIVLAARI.

GIVLAARI can cause:

  • Severe allergic reaction
    Tell your doctor or nurse right away if you experience any of the following signs or symptoms of a severe allergic reaction during treatment:
    • Swelling — mainly of the lips, tongue or throat which makes it difficult to swallow or breathe
    • Breathing problems or wheezing
    • Feeling dizzy or fainting
    • Rash or hives
    • Itching

    If you have a severe allergic reaction, your doctor or nurse will stop GIVLAARI treatment right away and you may need to take other medicines to control the symptoms.

  • Liver problems
    Your doctor will check your liver function by doing blood tests:
    • Before you start using GIVLAARI
    • Once a month for the first 6 months of treatment
    • And when they think it is needed

    If these tests show abnormal results, your doctor or nurse will decide whether to temporarily interrupt or stop treatment with GIVLAARI.

  • Kidney problems
    Your doctor will check how your kidneys are working while you are using GIVLAARI.
  • Injection site reactions
    GIVLAARI is given as an injection under the skin (called a “subcutaneous injection”). Reactions to this injection may happen during treatment with GIVLAARI.
    Tell your doctor or nurse right away if you experience any of the following symptoms of an injection site reaction during treatment: redness, pain, itchiness, rash, discoloration, or swelling around the injection site.
  • Increased blood homocysteine levels
    GIVLAARI may cause increased levels of homocysteine (a type of amino acid) in your blood. Your doctor will check your homocysteine levels before and during treatment by doing blood tests. If your levels are increased, your doctor may check your folate, vitamins B12 and B6, and tell you to take a vitamin B6 supplement.

What are the common side effects of GIVLAARI?
The most common side effects of GIVLAARI are nausea and injection site reactions. These are not all the possible side effects of GIVLAARI. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

WHAT IS GIVLAARI® (givosiran)?

GIVLAARI is a prescription medicine used to treat acute hepatic porphyria (AHP) in adults.

For additional information about GIVLAARI, please see the full Prescribing Information at https://www.alnylam.com/sites/default/files/pdfs/GIVLAARI-Prescribing-Information.pdf.

GIVLAARI and its associated logo are trademarks of Alnylam Pharmaceuticals, Inc. © 2023 Alnylam Pharmaceuticals, Inc. All rights reserved.

Sponsored by Alnylam Pharmaceuticals, Inc. AS1-USA-01513

What You Need to Know About Hepatitis C This Recovery Month

2023-09-08T14:01:02

(BPT) – Hepatitis C (HCV) is often referred to as the ‘silent disease’ due to silent symptoms that may not appear until years after exposure. In fact, of the more than 2 million Americans who are living with HCV, it is estimated that 40% are unaware of their condition.1

In the past ten years, cases of acute HCV have more than doubled with the opioid epidemic and substance use exacerbating the rise, and COVID-19 further limiting access to care.2-4 If left untreated, HCV can cause serious health problems, including liver damage, scarring of the liver (cirrhosis), liver cancer and even death.1

Fortunately, about 95% of chronic HCV cases can be cured with available treatments, and the virus can be detected through a simple blood test.1,5

This National Recovery Month, opioid addiction advocate Devin Lyall, the Founding Executive Director at Wilkes Recovery Revolution, Dr. Ada Stewart, family physician at Eau Claire Cooperative Health Centers and Gilead Sciences are encouraging testing and treatment for HCV, especially in vulnerable populations where substance use continues to impact communities.

Impact of the Opioid Crisis on HCV in the U.S.

In the United States, injection drug use is the leading cause of HCV transmission and comes with the risk of acquiring other blood-borne diseases such as HIV underscoring the need for awareness and screening among those affected by the opioid addiction crisis.1,6 One person living with HCV who injects drugs is likely to transmit HCV to an estimated 20 other people through sharing equipment used to consume drugs.7 While the Southern and Appalachian regions are most impacted by the opioid crisis and have the highest increase in acute HCV cases, the impact is felt around the country with each community facing their own set of challenges.8

“As someone who experienced opioid addiction and has been cured of hepatitis C, I know first-hand how important it is to raise awareness of the impact of this crisis,” said Devin. “This is why I’m passionate about helping others in this situation and educating on the connection between the opioid epidemic, especially in vulnerable populations — if we can provide people a safer way to consume drugs that reduces risk of spreading transmittable diseases, like HCV, while working with them on their recovery journey, it not only positively impacts that individual, but our community as a whole.”

HCV Screening & Finding Care

Screening is the only way to know if someone is living with HCV. For this reason, the Centers for Disease Control (CDC) recommends every adult be tested for HCV at least once in their lifetime as well as those with risk factors should be screened yearly.1,5 However, during the recent COVID-19 pandemic HCV screening decreased by 25% compared to the year before due to several barriers — housing instability, medical provider availability, opioid addiction and financial concerns — that may have impacted access to treatment and care services.9

“By prioritizing vulnerable populations for HCV care, such as people who are experiencing addiction, we can advance national efforts to screen, treat and cure HCV,” said Dr. Stewart. “These individuals are often stigmatized or deprioritized for care due to concerns about adherence or potential drug interactions, but the data show this is not the case and that an increase in screening and linkage to care can lead to people being cured of HCV in these communities.”

Moving Toward HCV Elimination

As a nation, there is a need to work together to achieve the shared goal of HCV elimination — bringing together national and state governments, policymakers, public health officials, physicians, and community organizations to ensure vulnerable communities are not left behind or forgotten. Gilead Sciences has implemented several public and private partnerships during National Recovery Month and beyond to facilitate HCV care through efforts such as Gilead Relink as well as the FOCUS, HepConnect and LEGA-C programs with the goal to advance HCV testing and linkage to care.

Visit HepCHope.com to learn more about HCV testing and find support.


1 Centers for Disease Control and Prevention. (2023, February 6). Hepatitis C: By the numbers. Centers for Disease Control and Prevention. https://www.cdc.gov/nchhstp/newsroom/fact-sheets/hepatitis/hepatitis-c-by-the-numbers.html

2 Centers for Disease Control and Prevention. (2022a, August 18). 2020 viral hepatitis surveillance report. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis/statistics/2020surveillance/index.htm

3 Perlman, D. C., & Jordan, A. E. (2018, April). The syndemic of opioid misuse, overdose, HCV, and HIV: Structural-level causes and interventions. Current HIV/AIDS reports. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884743/

4 Centers for Disease Control and Prevention. (2022, August 19). 2020 viral hepatitis surveillance national profile of viral hepatitis. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis/statistics/2020surveillance/introduction/national-profile.htm

5 Centers for Disease Control and Prevention. (2020, June 26). What to expect when getting tested for hepatitis C. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis/hcv/HepatitisCTesting.htm

6 Centers for Disease Control and Prevention. (2021, April 21). HIV and injection drug use. Centers for Disease Control and Prevention. https://www.cdc.gov/hiv/basics/hiv-transmission/injection-drug-use.html

7 U.S. Department of Health and Human Services. (2023, July 20). Viral hepatitis. National Institutes of Health. https://nida.nih.gov/research-topics/viral-hepatitis

8 Centers for Disease Control and Prevention. (2022c, August 30). 2020 rates of acute hepatitis C cases by State. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis/statistics/2020surveillance/hepatitis-c/figure-3.3.htm

9 Gamkrelidze A;Handanagic S;Shadaker S;Turdziladze A;Tsereteli M;Getia V;Aslanikashvili A;Surguladze S;Gvinjilia L;Kuchuloria T;Tskhomelidze I;Armstrong PA; (n.d.). The impact of covid-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia. Public health. https://pubmed.ncbi.nlm.nih.gov/35305459/